Investment
Features
FeesSafety
Academy
More
Pluang+

Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs Viatris Inc (VTRS) Price & Performance

T-Rex 2X Long MSTR Daily Target ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

T-Rex 2X Long MSTR Daily Target ETF vs Viatris Inc — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $39.7 (market cap $809.00M), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 24.8× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Viatris Inc pays a 2.75% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Long MSTR Daily Target ETF for 18 Days and Viatris Inc for 57 Days on average.

MSTUVTRS
Market Cap
$809.00M$20.03B
Volume
4,577,46514,109,977
Sector
Leveraged / InverseHealth
52-Week High
$432.00$18.27
52-Week Low
$14.60$9.74
Typical Hold Time
18 Days57 Days
Enterprise Value
—$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

T-Rex 2X Long MSTR Daily Target ETF

MSTU is trading at $38.33, down 2.84% on the day, with a bearish technical outlook as moving averages signal selling pressure. The stock recently underwent a 10:1 reverse stock split effective August 24, 2026, and declared a $0.29 dividend payable August 26, 2026. Key support levels are at $37 and $35, while resistance sits at $40 and $41.

The outlook remains cautious due to the bearish technical setup and lack of current fundamental data. Investment opportunities hinge on the company's ability to demonstrate improved financial performance post-reverse split, while risks include continued technical weakness and potential volatility from the leveraged ETF structure.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MSTU
43% Buy57% Sell
Avg holding period · 18 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About T-Rex 2X Long MSTR Daily Target ETF

MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.

Read more on MSTU →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →